CN102863365A - Crystalline pharmaceutical compound and preparation method and usage thereof - Google Patents
Crystalline pharmaceutical compound and preparation method and usage thereof Download PDFInfo
- Publication number
- CN102863365A CN102863365A CN2012102344828A CN201210234482A CN102863365A CN 102863365 A CN102863365 A CN 102863365A CN 2012102344828 A CN2012102344828 A CN 2012102344828A CN 201210234482 A CN201210234482 A CN 201210234482A CN 102863365 A CN102863365 A CN 102863365A
- Authority
- CN
- China
- Prior art keywords
- carboxymethyl
- cys
- ammonium salt
- crystallization
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an S-(carboxymethyl)-L-cysteine ammonium salt water crystalline pharmaceutical compound (having the following structural formula) and a preparation method and the application of the compound in the preparation of medicines for eliminating phlegm as well as medicines for preventing and treating respiratory system diseases such as chronic obstructive pulmonary diseases (COPD) and the like. After the compound is adopted, the COPD model rat airway resistance is remarkably reduced, the generation of oxide is reduced, the antioxidant level is increased, and the damage of oxide, inflammatory mediator and the like to the lung can be relieved.
Description
Technical field
The invention belongs to chemical pharmacy field, particularly, the present invention relates to a kind of S-(carboxymethyl)-halfcystine medical compounds and its production and use.
Background technology
S-carboxymethylcysteine, chemistry S-(carboxymethyl) by name-Cys (carbocisteine, carboxymethylcysteine, CMC), at first developed by French Joullie company in 1961 and be applied to clinical, be mucolytic drugs, can affect the secretion of segmental bronchus body of gland, the secretion of low viscous sialomucin is increased, the mucinous generation of full-bodied rock algae reduces, and can directly act on mucinous disulfide linkage, make the cracking of Saliva Orthana molecule and reduce the sputum viscosity, be easy to bring up; Can improve mucociliary clearance; Reduce airway hyperreactivity.Easily slough carboxymethyl after CMC enters in the body and form halfcystine, its contained sulfydryl can interact with the electrophilic group of active oxygen (reactive oxygen species, ROS) etc., brings into play direct antioxygenation; In addition, halfcystine also is the precursor of gsh (GSH), can have bioactive GSH by resynthesis, increases the concentration of GSH in the body, plays indirect antioxygenation.The CMC oral absorption is good, and is rapid-action, and taking 4 hours is visible obvious curative effects, is used for the treatment of thick sputum and dys-expectoration that the diseases such as chronic bronchitis, pulmonary emphysema, chronic obstructive pulmonary disease (COPD), bronchial asthma cause.
Chronic obstructive pulmonary disease (chronic obstructive pulmonary disease, COPD) is that a kind of flow limitation is feature, and flow limitation is not exclusively reversible, be carry out sexual development chronic respiratory system diseases.Announce according to the World Health Organization, COPD is only second to heart trouble, cerebro-vascular diseases and acute pulmonary infection in the middle of global disease death reason, with the acquired immune deficiency syndrome (AIDS) position that is locked in a tie for fourth.In the world, be subjected to the patient of this disease puzzlement to reach 600,000,000, the annual patients with COPD total number of persons of China can reach 2,700 ten thousand.At present, COPD improves patient's symptom by pharmacological agent, reduces the acute exacerbation of disease.
2006, Japanese scholars Yasuda H carries out random double blind test, the result shows that COPD patient takes CMC (1500mg/d for a long time in a large number, 12 months) can reduce the frequency of disease development of flu and slow down COPD acute exacerbation (Yasuda H, Yamaya M, Sasaki T, et al.Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease.J Am Geriatr Soc.2006; 54 (2): 378-80.).Japanese scholars Tatsumi K carried out the flat row stochastic test of multicenter in 2007, selected 142 COPD patients, the result shows, CMC takes CMC (1500mg/d for a long time in a large number, 12 months) to COPD acute attack tool prophylactic effect, St George ' s questionnaire etc. studies show that and also can improve patients ' life quality (Tatsumi K, Fukuchi Y.Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease.J Am Geriatr Soc.2007; 55 (11): 1884-6.).2008, Zhong Nanshan etc. studied discovery, and long-term a large amount of (1500mg/d, 12 months) take the acute attack that S-carboxymethylcysteine can better prevent chronic obstructive pulmonary disease, and annual everyone acute attack rate can reduce 24.5%.Its curative effect is close to suction cortin associating long-acting beta agonist or the long-acting anticholinergic thing of international standard, and its result for the treatment of is not subjected to the impact of chronic obstructive pulmonary disease severity and drug combination, than the Inhalation in Treating method of international standard, medical expense can reduce 85%.This result of study shows, S-carboxymethylcysteine has extraordinary application prospect (Jin-Ping Zheng for the treatment of chronic obstructive pulmonary disease, Nan-Shan Zhong, etc.Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebo-controlled study.Lancet, 2008; 371:2013-18).
S-carboxymethylcysteine is as a kind of expelling phlegm drugs, production and use in China are very general, but have two carboxyls in the structure of S-carboxymethylcysteine, are acid, so that this medicine has hormesis to digestive tube, can cause have a stomach upset, feel sick, the untoward reaction such as vomiting, intestines and stomach are hemorrhage.If this medicine easy damaged gastrointestinal mucosa of long-term taking causes the serious side effects such as hemorrhage, ulcer even perforation.Clearly indicate in the package insert " digestive tract ulcer active period patient forbidding ".Therefore, seek safely and effectively S-carboxymethylcysteine surrogate, be significant for the treatment of the diseases such as COPD.
Summary of the invention
The purpose of this invention is to provide the medical compounds, particularly S-(carboxymethyl) of a kind of S-(carboxymethyl)-halfcystine-Cys ammonium salt one water crystallization.
Another object of the present invention provides the preparation method of the preparation method, particularly S-(carboxymethyl) of the medical compounds of a kind of S-(carboxymethyl)-halfcystine-Cys ammonium salt one water crystallization.
A further object of the present invention provides the composition of the medical compounds that comprises S-(carboxymethyl)-halfcystine, particularly comprises the pharmaceutical composition of S-(carboxymethyl)-Cys ammonium salt one water crystallization.
Of the present inventionly advance the medical compounds that a purpose provides S-(carboxymethyl)-halfcystine, S-(carboxymethyl)-Cys ammonium salt one water crystallization particularly, application in the preparation expelling phlegm drugs, and the application in the medicament for treating respiratory system things such as preparation prevention and treatment chronic obstructive pulmonary.
The objective of the invention is to realize by following concrete technical scheme:
The medical compounds of a kind of S-(carboxymethyl)-halfcystine, shown in general formula (I):
Wherein:
R be pharmaceutically acceptable can with the basic cpd of S-(carboxymethyl)-halfcystine salify, x is 1～2 integer, y is 1～5 integer.
General formula of the present invention (I) medical compounds, wherein R can be ammonia or arginine.
General formula of the present invention (I) medical compounds, wherein R does not comprise Methionin.
Compound of the present invention is selected from S-(carboxymethyl)-halfcystine ammonium salt monohydrate, and its structural formula is suc as formula (II).
Its levoisomer is S-(carboxymethyl)-Cys ammonium salt one water crystallization compound, and its structural formula is suc as formula (III).
The present invention further also provides a kind of S-(the carboxymethyl)-medical compounds of halfcystine and the preparation method of isomer thereof, and the method is with S-(carboxymethyl)-halfcystine dissolving or is suspended in the suitable solvent system that preferred solvent is water; Add basic cpd R, fully reaction make solid molten clear after, in reaction solution, add the crystallization solvent, separation, the medical compounds crystallization that gets S-(carboxymethyl)-halfcystine.
" the crystallization solvent " mentioned in the aforesaid method can be regarded as and this reaction product sl. sol. solvent at the most, according to the technical field under the method, dilution crystallization method (or solvent crystallization) is that solute is dissolved in water or other organic solvents, then add certain solvent in the xln solubleness of solute in former solvent is reduced, thus the crystallization method that solute is separated out fast.The solvent that adds is known as crystallization solvent or precipitation agent.
The medical compounds of the S-of making of the present invention (carboxymethyl)-halfcystine and the crystallization solvent that isomer crystallizes is separated out thereof are that to contain C be 1～4 alcohol, such as ethanol, Virahol, n-propyl alcohol, propyl carbinol, 2-butanols; Contain C and be 3～6 ketone, such as acetone, methylethylketone, pentanone; Contain C and be 2～4 nitrile, such as acetonitrile, propionitrile; Contain C and be 2～6 ethers, such as dioxan, tetrahydrofuran (THF); Contain C and be 1～5 amides, such as DMF, N,N-dimethylacetamide; Or more than one combination of above-mentioned solvent.
Particularly, the invention provides the preparation method of S-(carboxymethyl)-Cys ammonium salt one water crystallization compound, the method also can be used for the preparation of S-(carboxymethyl)-Cys ammonium salt one water crystallization isomeric compound, and the method is as follows:
With S-(carboxymethyl)-Cys dissolving or suspend in water, under 20～60 ℃, add an amount of ammoniacal liquor, stirring is fully reacted it, reaction solution molten clear after, add the crystallization solvent, make crystallization, the S-(carboxymethyl) that separation obtains-Cys ammonium salt one water crystallization compound.
Among the above-mentioned preparation method, the detailed process step that is appreciated that is:
(1), with S-(carboxymethyl)-Cys dissolving or be suspended in the suitable solvent system, preferred solvent is water; Under 20～60 ℃, add at least the proper ammonia with S-(carboxymethyl)-Cys equimolar ratio, fully stir S-(carboxymethyl)-Cys and ammoniacal liquor are reacted completely, reaction solution is fully molten clear;
(2), in reaction solution, add the crystallization solvent, namely with reaction product S-(carboxymethyl)-Cys ammonium salt one water crystallization sl. sol. solvent at the most, S-(carboxymethyl)-Cys ammonium salt one water crystallization is progressively reached capacity or hypersaturated state, get final product crystallize out, by continuous adding solvent, control supersaturation process and crystalline growth velocity, it is good that the crystal of separating out is practised, S-(carboxymethyl)-Cys ammonium salt one water crystallization crystal is fully separated out, separate, drying gets S-(carboxymethyl)-Cys ammonium salt one water crystallization.
Above-described Crystallization Process also can join the reaction solution of S-(carboxymethyl)-Cys and ammoniacal liquor in the crystallization solvent (with S-(carboxymethyl)-Cys ammonium salt one water crystallization sl. sol. solvent at the most), after crystal is fully separated out, separate, drying can get S-(carboxymethyl)-Cys one water crystallization equally.
No matter above-described crystallization method is batch crystallization, continuous crystallisation, stirred crystallization, leaves standstill the crystallization operation modes such as crystallization, can implement.
Crystallization solvent described in the preparation method of above S-(carboxymethyl)-Cys ammonium salt one water crystallization compound is that to contain C be 1～4 alcohol, such as ethanol, Virahol, n-propyl alcohol, propyl carbinol, 2-butanols; Contain C and be 3～6 ketone, such as acetone, methylethylketone, pentanone; Contain C and be 2～4 nitrile, such as acetonitrile, propionitrile; Contain C and be 2～6 ethers, such as dioxan, tetrahydrofuran (THF); Contain C and be 1～5 amides, such as DMF, N,N-dimethylacetamide; Or more than one combination of above-mentioned solvent.These solvents or solvent mixture and water soluble and with S-(carboxymethyl)-Cys ammonium salt one water crystallization slightly soluble.
Preferred solvent is ethanol, acetone, Virahol, acetonitrile or their binary, ternary or multicomponent mixture.
The solvability table (25 ℃) of S-(carboxymethyl)-Cys ammonium salt one water crystallization in several solvents:
| The solvent title | Solvability |
| Methyl alcohol | Soluble,very slightly |
| Virahol | Soluble,very slightly |
| Dehydrated alcohol | Soluble,very slightly |
| Acetone | Soluble,very slightly |
| Acetonitrile | Soluble,very slightly |
| DMF | Soluble,very slightly |
S-of the present invention (carboxymethyl)-Cys ammonium salt one water crystallization size-grade distribution is comparatively even, after storing for some time under the normal temperature, proterties is not observed obvious variation, and character is comparatively stable, be difficult for the moisture absorption, the moisture content difference that records after placement for some time is little.
Being used in combination following various analytical procedure analyzes the specific crystal formation sample of S-(carboxymethyl)-Cys ammonium salt monohydrate: X-ray powder diffraction analytical method (hereinafter claiming XRPD), dsc (hereinafter claiming DSC), thermogravimetry (hereinafter claiming TG), fusing point, solid state nmr method, ion chromatography, infrared spectroscopy.Because the data that different instruments and different condition can cause producing can be slightly different, therefore the following numerical value of quoting is not considered as absolute numerical value.
X ray diffracting data is obtained by the D/max-3A X-ray diffractometer, adopts Cu-K α
1The following X-ray powder diffraction pattern (accompanying drawing 14) that radionetric survey is expressed with Bragg angle 2 θ, relative intensity (to express with respect to the percentage ratio of strong ray):
That as above carries depends on used measuring condition, and the intensity at each peak can change to some extent on the XRPD diffractogram, does not therefore use the numeral relative intensity, but uses following intensity definition:
| The % relative intensity | Definition |
| 25-100 | VS (very strong) |
| 10-25 | S (by force) |
| 3-10 | M (medium) |
| 1-3 | W (weak) |
8.5 °, 19.7 °, 21.5 °, 23.5 °, 27.5 °, 29.2 ° and 32.5 ° of diffraction angle of the X-ray diffractogram of above-mentioned data acknowledgement S-(carboxymethyl)-Cys ammonium salt monohydrate (2 θ angle ± 0.2 °) locate to have characteristic peak.
Infared spectrum is obtained by FT-IR NICOLET 6700 instruments, and it is the charateristic avsorption band of carboxylate salt that the infared spectrum (Figure 15) of the KBr compressing tablet of S-(carboxymethyl)-Cys ammonium salt monohydrate has following charateristic avsorption band: 1600-1610cm-1,1550-1559cm-1,1400-1410cm-1;-N-H absorption frequency is also in this scope of 1600-1610cm-1,1550-1559cm-1, and is overlapping to some extent with the absorption of carboxylate salt; 1470-1480cm-1 is-the C-H-absorption peak.
The infared spectrum of the KBr compressing tablet of above-mentioned data acknowledgement S-(carboxymethyl)-Cys ammonium salt one water crystallization medical compounds has 1600-1610cm-1,1550-1559cm-1,1470-1480cm-1,1400-1410cm-1 charateristic avsorption band.
Analyze with the Optimelt melting point apparatus, between 115-119 ℃, observe S-(carboxymethyl)-Cys ammonium salt monohydrate and melt.
The TG data are obtained by German NETZSCH company's T G209 instrument, under air atmosphere, are warming up to 350 ℃ with the speed of 10 ℃/min, the record thermogravimetric curve.As shown in figure 10, the TG differential thermogram has shown at 55 ℃ of left and right sides compounds and has begun weightlessness that 95-135 ℃ of scope internal loss is about 8～9%, and be consistent with the theoretical content 8.4% of water in S-(carboxymethyl)-Cys ammonium salt monohydrate.
The DSC the data Germany NETZSCH DSC204 of company instrument is analyzed, and is warming up to 165 ℃ with 10 ℃/min speed under nitrogen atmosphere, the record heating curve.Shown in the DSC figure (Fig. 9), the peak value (heat-absorbing action is about 55 ℃ of beginnings) about about 95 ℃ of heat absorption has for the second time heat-absorbing action about 117 ℃ for the first time.With reference to measured fusing point and TG data, showing in the process of heating S-(carboxymethyl)-Cys ammonium salt monohydrate has the dehydration phenomenon about 95 ℃, is the fusing heat absorption about 117 ℃.TG and DSC data results show that S-(carboxymethyl)-Cys ammonium salt monohydrate desolvation point is in 55-115 ℃ of scope.
Adopt Bruker AVANCE AV400 million superconduction pulse fourier transform nmr spectrometers to carry out structural characterization (Figure 11 and Figure 12), S-(carboxymethyl)-Cys ammonium salt monohydrate has following principal character:
1H-NMR (D
2O, 400MHz) δ: 3.04 (m, 1H, CH
2), 3.16 (m, 1H, CH
2), 3.30 (m, 2H, CH
2), 3.91 (m, 1H, CH);
13C-NMR (D
2O, 400MHz) δ: 178.07 (C-5), 173.25 (C-1), 54.16 (C-2), 37.52 (C-4), 33.91 (C-3).
The chromatography of ions result (Figure 13) who adopts Dionex DX-600 instrumental analysis to obtain shows NH
4 +% content is 8.35～8.50%, NH in this and S-(the carboxymethyl)-Cys ammonium salt monohydrate
4 +Theoretical content is consistent.
After the present invention uses S-(carboxymethyl)-Cys and pharmaceutically acceptable suitable inorganic base salts or organic bases salify, be hydrolyzed in vivo after being absorbed by the body and generate S-(carboxymethyl)-Cys, when keeping S-(carboxymethyl)-Cys drug effect, can reduce the acidity of S-(carboxymethyl)-Cys to gastral stimulation, reduce its side effect.
Preferred version S-of the present invention (carboxymethyl)-Cys ammonium salt one water crystallization compound is the solubility double salt that utilizes the alkalescence of the acidity of its carboxyl and ammoniacal liquor to form.S-(carboxymethyl)-Cys ammonium salt one water crystallization is very easily water-soluble, can under the hydrochloric acid in gastric juice effect, be hydrolyzed into S-(carboxymethyl)-Cys and ammonium chloride after being absorbed by the body, can not only reduce S-(carboxymethyl)-Cys to GI stimulation, unnecessary hydrochloric acid in gastric juice also can neutralize.After S-(carboxymethyl)-Cys ammonium salt one water crystallization hydrolysis, S-(carboxymethyl)-Cys continues to bring into play its pharmacological action in vivo, simultaneously, the ammonium chloride that hydrolysis generates has chemical irritation to mucous membrane, energy reflectivity ground increases amount of expectoration, makes sputum be easy to discharge, and is conducive to be difficult for a small amount of removing of gluing phlegm of expectoration, to the synergism of having reduced phlegm of S-(carboxymethyl)-Cys, more be conducive to improve curative effect.The security of S-(carboxymethyl)-Cys ammonium salt is good, and side effect is little, can be used for the Disease long-term takings such as chronic obstructive pulmonary disease.
The present invention also provides a kind of pharmaceutical composition, comprise take S-(carboxymethyl)-halfcystine medical compounds as effective constituent and must use carrier, more specifically, be pharmaceutical composition take S-(carboxymethyl)-Cys ammonium salt one water medical compounds as effective constituent and pharmaceutically acceptable carrier.
The present invention also provides the medical compounds of such S-(carboxymethyl)-halfcystine, the particularly application of S-(carboxymethyl)-Cys ammonium salt one water crystallization compound in the preparation expelling phlegm drugs, and the application in preparation prevention and treatment chronic obstructive pulmonary medicament for treating respiratory system thing.
The effect of drugs experiment
1. experimental technique
1.1 the preparation of rat copd model
90 rats are divided into 6 groups at random, are respectively normal group, model group, positive group, high, normal, basic dosetest group, 15 every group.Adopt the method that splashes into induced by lipopolysaccharide (LPS) in the at present internal and international upper fumigation gas-adding pipe of generally using to set up the rat copd model.Cycle is 3 months (90 days).Concrete grammar: at the 1st, 15,29,43,57,71,85 day of test, use the etherization rat, pull out the root of the tongue of rat, splash into LPS (200ug/200ul) with elbow gavage syringe needle through tracheae.Normal group splashes into the physiological saline of equivalent, not fumigation with identical method.All the other 5 groups of rats place homemade fumigation storehouse fumigation every day.The external negative pressure pump of fumigation storehouse one side, the top is connected to the socket of cigarette.Connect the electric current of negative pressure pump, igniting cigarette can enter the fume extraction of cigarette in the fumigation storehouse.Dead because of anoxic in order to prevent animal, light 12 cigarettes at every turn, open Cang Gai behind the fumigation 20min and renew bright air.1h/3 times/day, add with elbow gavage syringe needle and splash into LPS (200ug/200ul) through tracheae.
1.2 drug intervention
Experiment totally 90 days, began to carry out drug intervention on the 15th day from experiment, positive group perfusion S-carboxymethylcysteine, high test group perfusion various dose trial drug (being S-carboxymethyl Cys ammonium salt one water crystallization) in hanging down, the physiological saline of model group and normal rats perfusion equivalent.
1.3 index determining
The second day eye socket is got blood after experiment finishes, separation of serum and leave and take lung tissue, get right upper lung and carry out the pathologic detection, after remaining lung carries out lung tissue homogenate, measure oxidative and anti-oxidative index lipid peroxide (LPO), mda (MDA), reduced glutathion (GSH) content and superoxide-dismutase (SOD) activity, the concentration of inflammatory mediator TNF-α, IL-8, IL-6.Carry out without the lung function tests of creating and have wound.
2. experimental result
2.1 animal performance in the experimentation
Normal rats is vivaciously active, the hair polishing, color and luster is arranged; Model and administration treated animal integrality are not good enough, cough, One's spirits are drooping, tired sleeping successively occurs, be slow in action, the withered jaundice of hair, mixed and disorderly, the sings and symptoms such as come off.
2.2 pathological change
Normal rats tunica mucosa bronchiorum epithelial structure is relatively complete, the cilium marshalling, and rare obviously inflammatory cell infiltration under the mucous membrane, the alveolar structure continuous whole, alveolar space has no obvious expansion and inflammatory exudation (seeing attached Fig. 1 and 2).The narrow distortion of model group rat bronchiole even obturation; Cilium adhesion, lodging have obviously to come off, and the air flue mucosal degeneration is downright bad, and epithelial cell, the remarkable hyperplasia of goblet cell have massive inflammatory cells infiltrated under the film and around the bronchiole, take lymphocyte as main; The airway smooth muscle hyperplasia, lung arteriole unstriated muscle thickens; Pulmonary emphysema are obvious, and visible bulla forms (seeing accompanying drawing 3 and 4).Inflammatory cell infiltration, air flue mucosal degeneration degree of necrosis and lung arteriole proliferation of smooth muscle thickness are all light than model group under each medication group bronchial mucosa.The wherein narrow distortion of positive group rat bronchiole, cilium adhesion, lodging, the attenuation of part alveolus wall, alveolar space enlarges, inflammatory cell infiltration under the bronchial mucosa (seeing accompanying drawing 5 and 6).The narrow distortion of trial drug group rat bronchiole, mucous membrane lodges, comes off, and the air flue mucosal degeneration has lymphocytic infiltration under downright bad epithelial cell, the mucous membrane and around the bronchiole; The interstitial lung inflammatory cell infiltration.(seeing accompanying drawing 7 and 8).
2.3 the mensuration of Raw air way resistance
Under the identical operating pressure, compare with normal group, the model group rat is without wound and have the wound Raw air way resistance all significantly to increase (P＜0.01), shows the animal model success.Compare with model group, give trial drug treatment after, Raw air way resistance obviously reduces, and is a certain amount of effect relationship.Test-results sees Table 1.
Table 1 is on the impact of Raw air way resistance
Annotate: compare * * P＜0.01 with model group
2.4 the mensuration of inflammation index
Compare with normal group, TNF-α, IL-8, IL-6 content all significantly increase (P＜0.01) in model group induced lung and the serum, show the animal model success.Compare with model group, give simultaneously the trial drug treatment, TNF-α, IL-8, IL-6 content, and be a certain amount of effect relationship.Test-results sees Table 2.
Table 2 on the impact of inflammation index (
Pg/mL)
Annotate: compare * P＜0.05, * * P＜0.01 with model group
2.5 the mensuration of oxidation and Antioxidant Indexes
Compare with normal group, oxidation index LPO, MDA content all significantly increase (P＜0.01) in model group induced lung and the serum, and Antioxidant Indexes GSH and SOD content all significantly reduce cost (P＜0.01), show the animal model success.Compare with model group, give simultaneously the trial drug treatment, LPO, MDA content all significantly reduce in lung and the serum, and GSH and SOD content all significantly raise, and are a certain amount of effect relationship.Test-results sees Table 3 and table 4.
Table 3 is on the impact of oxidation index
Annotate: compare * P＜0.05, * * P＜0.01 with model group
Table 4 is on the impact of Antioxidant Indexes
Annotate: compare * P＜0.05, * * P＜0.01 with model group
3. experiment conclusion
The key character of COPD is the persistence inflammatory disorders of whole air flue and pulmonary parenchyma, and oxidation antioxidation is unbalance, and vivo oxidation stress strengthen.Preliminary drug effect result shows, the COPD rat model gives trial drug simultaneously in modeling in the time of the 15th day can significantly reduce Raw air way resistance under the uniform pressure, reduce the generation of oxide compound, increase the level of antioxidant, oxidation-antioxidation is tended to balance, alleviate oxide compound, inflammatory mediator etc. to the damage of lung, this is consistent with the result that pathology section examination arrives.
Beneficial effect
Gained S-of the present invention (carboxymethyl)-Cys medical compounds, particularly S-(carboxymethyl)-Cys ammonium salt one water crystallization is a kind of well-crystallized that distributes than uniform particle size, stable in properties, be difficult for the moisture absorption, be easy to preserve and make the relative medicine preparation.The easy easy control of preparation method of this S-(carboxymethyl)-Cys medical compounds, particularly S-(carboxymethyl)-Cys ammonium salt one water crystallization, yield is high, and with short production cycle, environmental pollution is little, is conducive to large-scale production and application.Preliminary drug effect result shows that compound of the present invention can significantly reduce COPD rat model Raw air way resistance, reduces the generation of oxide compound, increases the level of antioxidant, alleviates oxide compound, inflammatory mediator etc. to the damage of lung.
Description of drawings
Accompanying drawing 1 is depicted as normal rats pathologic section, HE dye (* 100).
Accompanying drawing 2 is depicted as normal rats pathologic section, HE dye (* 200).
Accompanying drawing 3 is depicted as model group lung tissue of rats pathological section, HE dye (* 100).
Accompanying drawing 4 is depicted as model group lung tissue of rats pathological section, HE dye (* 200).
Accompanying drawing 5 is depicted as positive group lung tissue of rats pathological section, HE dye (* 100).
Accompanying drawing 6 is depicted as positive group lung tissue of rats pathological section, HE dye (* 200).
Accompanying drawing 7 is depicted as rats in test groups pathologic section, HE dye (* 100).
Accompanying drawing 8 is depicted as rats in test groups pathologic section, HE dye (* 200).
Accompanying drawing 9 is depicted as the DSC figure of S-(carboxymethyl)-Cys ammonium salt monohydrate.
Accompanying drawing 10 is depicted as the TG figure of S-(carboxymethyl)-Cys ammonium salt monohydrate.
Accompanying drawing 11 is depicted as S-(carboxymethyl)-Cys ammonium salt monohydrate
1H-NMR figure.
Accompanying drawing 12 is depicted as S-(carboxymethyl)-Cys ammonium salt monohydrate
13C-NMR figure.
Accompanying drawing 13 is depicted as the chromatography of ions figure of S-(carboxymethyl)-Cys ammonium salt monohydrate.
Accompanying drawing 14 is depicted as the x ray powder diffraction pattern of S-(carboxymethyl)-Cys ammonium salt monohydrate.
Accompanying drawing 15 is depicted as the infrared spectrogram of S-(carboxymethyl)-Cys ammonium salt monohydrate.
Embodiment
Below with specific examples technical scheme of the present invention is described, protection scope of the present invention is not limited to this.
The preparation of S-(carboxymethyl)-Cys ammonium salt one water crystallization:
Under the room temperature, in the there-necked flask of whipping appts is housed, add 50g S-(carboxymethyl)-Cys, 40ml distilled water, add 25ml 25% ammoniacal liquor in the suspension liquid that obtains, rapid stirring gets settled solution again, to wherein dripping 600ml ethanol, rate of addition is slightly fast during beginning, the rate of addition that when the adularescent crystal is separated out, slows down, after ethanol dropwises, 25 ℃ of lower growing the grains, suction filtration, a small amount of washing with alcohol filter cake is drained drying, get white S-(carboxymethyl)-Cys ammonium salt one water crystallization 56.5g, yield about 94.5%.
Under the room temperature, in the there-necked flask of whipping appts is housed, add 25g S-(carboxymethyl)-Cys, 20ml distilled water, add 14ml 25% ammoniacal liquor in the suspension liquid that obtains, rapid stirring gets settled solution again, to wherein dripping the 400ml Virahol, rate of addition is slightly fast during beginning, the rate of addition that when the adularescent crystal is separated out, slows down, after Virahol dropwises, 25 ℃ of lower growing the grains, suction filtration, a small amount of washed with isopropyl alcohol filter cake is drained drying, get white S-(carboxymethyl)-Cys ammonium salt one water crystallization 28.5g, yield about 95.4%.
Embodiment 3
Under the room temperature, in the there-necked flask of whipping appts is housed, add 50g S-(carboxymethyl)-Cys, 40ml distilled water, add 30ml 25% ammoniacal liquor in the suspension liquid that obtains, rapid stirring gets settled solution again, to wherein dripping 600ml acetone, rate of addition is slightly fast during beginning, the rate of addition that when the adularescent crystal is separated out, slows down, after acetone dropwises, 25 ℃ of lower growing the grains, suction filtration, a small amount of washing with acetone filter cake is drained drying, get white S-(carboxymethyl)-Cys ammonium salt one water crystallization 57.4g, yield about 96.0%.
Embodiment 4
Under the room temperature, in the beaker of whipping appts is housed, add 25g S-(carboxymethyl)-Cys, 20ml distilled water adds 14ml 25% ammoniacal liquor again in the suspension liquid that obtains, and rapid stirring gets settled solution, and is for subsequent use; In the there-necked flask that whipping appts is housed, add 400ml acetone, heating in water bath to 50 ℃ stirs and lower settled solution in the beaker slowly is added dropwise in the acetone, and the adularescent crystal is separated out, dropwise the recession water-bath, 25 ℃ of lower growing the grains, suction filtration, a small amount of washing with acetone filter cake, drain, drying gets white S-(carboxymethyl)-Cys ammonium salt one water crystallization 28.2g, yield about 94.4%.
Embodiment 5
Under the room temperature, in the there-necked flask of whipping appts is housed, add 50g S-(carboxymethyl)-Cys, 40ml distilled water, add 30ml 25% ammoniacal liquor in the suspension liquid that obtains, rapid stirring gets settled solution again, to wherein dripping the 600ml acetonitrile, rate of addition is slightly fast during beginning, the rate of addition that when the adularescent crystal is separated out, slows down, after acetonitrile dropwises, 25 ℃ of lower growing the grains, suction filtration, a small amount of acetonitrile washing leaching cake is drained drying, get white S-(carboxymethyl)-Cys ammonium salt one water crystallization 58.5g, yield about 97.0%.
Embodiment 6
Under the room temperature, in the there-necked flask of whipping appts is housed, add 40g S-(carboxymethyl)-Cys, 30ml distilled water, add 24ml 25% ammoniacal liquor in the suspension liquid that obtains, rapid stirring gets settled solution again, to wherein dripping the 500ml tetrahydrofuran (THF), rate of addition is slightly fast during beginning, the rate of addition that when the adularescent crystal is separated out, slows down, after tetrahydrofuran (THF) dropwises, 25 ℃ of lower growing the grains, suction filtration, a small amount of washing with acetone filter cake is drained drying, get white S-(carboxymethyl)-Cys ammonium salt one water crystallization 26.5g, yield about 55.4%.
Embodiment 7
Under the room temperature, in the there-necked flask of whipping appts is housed, add 40g S-(carboxymethyl)-Cys, 30ml distilled water, add 24ml 25% ammoniacal liquor in the suspension liquid that obtains, rapid stirring gets settled solution again, to wherein dripping 500ml methyl alcohol, rate of addition is slightly fast during beginning, the rate of addition that when the adularescent crystal is separated out, slows down, after methyl alcohol dropwises, 35 ℃ of lower growing the grains, suction filtration, a small amount of methanol wash filter cake is drained drying, get white S-(carboxymethyl)-Cys ammonium salt one water crystallization 44.95g, yield about 94.0%.
Under the room temperature, in the there-necked flask of whipping appts is housed, add 40g S-(carboxymethyl)-Cys, 30ml distilled water adds 24ml 25% ammoniacal liquor again in the suspension liquid that obtains, rapid stirring gets settled solution, to wherein dripping the 500ml DMF, rate of addition is slightly fast during beginning, rate of addition slows down when the adularescent crystal is separated out, after DMF dropwises, 45 ℃ of lower growing the grains, suction filtration, a small amount of washing with acetone filter cake is drained drying, get white S-(carboxymethyl)-Cys ammonium salt one water crystallization 46.8g, yield about 98.0%.
The sylvite of general formula I (in Carbocisteine) 1 mass parts
Chlorine is pricked aniline 0.1 mass parts
Water (add an amount of phosphoric acid salt and regulate pH to 6) 98.9 mass parts
With above-mentioned prescription drug and auxiliary materials and mixing, embedding can obtain sprays in the quantitative valve container.
Compound III (in Carbocisteine) 1 mass parts
Bromine is pricked aniline 0.1 mass parts
Water (add an amount of borate and regulate pH to 7) 98.9 mass parts
With above-mentioned prescription drug and auxiliary materials and mixing, embedding can obtain sprays in the quantitative valve container.
Embodiment 11
Compound III (in Carbocisteine) 1.5 mass parts
Bromine is pricked aniline 0.1 mass parts
Water (add an amount of borate and regulate pH to 7) 98.4 mass parts
With above-mentioned prescription drug and auxiliary materials and mixing, embedding can obtain sprays in the quantitative valve container.
Claims (8)
1. a S-(carboxymethyl)-Cys ammonium salt one water crystallization medical compounds, its structural formula is as follows,
The diffraction angle that it is characterized in that its X-ray diffractogram locates to have characteristic peak at 8.5 °, 19.7 °, 21.5 °, 23.5 °, 27.5 °, 29.2 ° and 32.5 °.
2. S-claimed in claim 1 (carboxymethyl)-Cys ammonium salt one water crystallization medical compounds is characterized in that the infared spectrum of its KBr compressing tablet has 1600-1610cm
-1, 1550-1559cm
-1, 1470-1480cm
-1, 1400-1410cm
-1Charateristic avsorption band.
3. the preparation method of a claim 1,2 described S-(carboxymethyl)-Cys ammonium salt one water crystallization medical compounds, it is characterized in that S-(carboxymethyl)-Cys being dissolved or suspending in water, under 20～60 ℃, add ammoniacal liquor, stirring is fully reacted it, reaction solution molten clear after, add the crystallization solvent, make crystallization, the S-(carboxymethyl) that separation obtains-Cys ammonium salt one water crystallization compound.
4. the preparation method of S-according to claim 3 (carboxymethyl)-Cys ammonium salt one water crystallization medical compounds is characterized in that the crystallization solvent is that to contain C be 1～4 alcohol, contains C to be 3～6 ketone, contains C to be 2～4 nitrile, contains C to be 2～6 ether, contains one or more the combination that C is 1～5 acid amides.
5. the preparation method of S-according to claim 4 (carboxymethyl)-Cys ammonium salt one water crystallization medical compounds is characterized in that containing C and is 1～4 alcohol and is selected from ethanol, Virahol, n-propyl alcohol, propyl carbinol, 2-butanols; Contain C and be 3～6 ketone and be selected from acetone, methylethylketone, pentanone; Containing C and be 2～4 nitrile is acetonitrile, propionitrile; Contain C and be 2～6 ether and be selected from diox, tetrahydrofuran (THF); Containing C and be 1～5 acid amides is DMF, N,N-dimethylacetamide.
6. pharmaceutical composition, comprising each described S-(carboxymethyl) in the claim 1,2-Cys ammonium salt one water crystallization medical compounds is effective constituent and pharmaceutically acceptable carrier.
7. each described S-(carboxymethyl) in the claim 1,2-Cys ammonium salt one water crystallization medical compounds is for the preparation of the application in the expelling phlegm drugs.
8. the application of each described S-(carboxymethyl) in the claim 1,2-Cys ammonium salt one water crystallization medical compounds in preparation prevention and treatment chronic obstructive pulmonary disease medicine.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210234482.8A CN102863365B (en) | 2011-07-07 | 2012-07-06 | Crystalline pharmaceutical compound and preparation method and usage thereof |
| PCT/CN2013/078856 WO2014005543A1 (en) | 2012-07-06 | 2013-07-05 | S-(carboxymethyl)-cysteine pharmaceutical compound and preparation method and use thereof |
| US15/508,761 US10251854B2 (en) | 2012-07-06 | 2013-07-05 | S-(carboxymethyl)-cysteine pharmaceutical compound and preparation method and use thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110190143 | 2011-07-07 | ||
| CN201110190143.X | 2011-07-07 | ||
| CN201210234482.8A CN102863365B (en) | 2011-07-07 | 2012-07-06 | Crystalline pharmaceutical compound and preparation method and usage thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102863365A true CN102863365A (en) | 2013-01-09 |
| CN102863365B CN102863365B (en) | 2014-04-16 |
Family
ID=47442530
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210234440.4A Active CN102863364B (en) | 2011-07-07 | 2012-07-06 | S-(carboxymethyl)-cysteine pharmaceutical compound and preparation method and usage thereof |
| CN201210234482.8A Active CN102863365B (en) | 2011-07-07 | 2012-07-06 | Crystalline pharmaceutical compound and preparation method and usage thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210234440.4A Active CN102863364B (en) | 2011-07-07 | 2012-07-06 | S-(carboxymethyl)-cysteine pharmaceutical compound and preparation method and usage thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN102863364B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014005543A1 (en) * | 2012-07-06 | 2014-01-09 | 广州白云山制药股份有限公司广州白云山制药总厂 | S-(carboxymethyl)-cysteine pharmaceutical compound and preparation method and use thereof |
| CN105311009A (en) * | 2014-07-31 | 2016-02-10 | 广州白云山医药集团股份有限公司白云山制药总厂 | Application of S-(carboxymethyl)-L-cysteine to preparation of medicines for preventing and treating respiratory system diseases |
| TWI665202B (en) * | 2016-08-01 | 2019-07-11 | 香港商永展國際有限公司 | Crystal of 5-((2-(6-amino)-9h-purin-9-yl)ethyl)amino)pentan-1-ol |
| TWI745289B (en) * | 2015-04-22 | 2021-11-11 | 大陸商江蘇恆瑞醫藥股份有限公司 | A crystalline form of cyclin-dependent protein kinase inhibitor and preparation methods thereof |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111333555B (en) * | 2018-01-05 | 2022-06-03 | 广州白云山医药集团股份有限公司白云山制药总厂 | S- (carboxymethyl) -L-ammonium cysteine anhydrous crystal form, preparation method and application thereof |
| CN108715582A (en) * | 2018-08-30 | 2018-10-30 | 浙江三门恒康制药有限公司 | A kind of preparation method of lysine carbocisteine |
| CN111074559A (en) * | 2019-12-31 | 2020-04-28 | 太仓宝霓实业有限公司 | Antibacterial phosphorus-free flame retardant and preparation method thereof |
| CN115974832B (en) * | 2023-02-27 | 2023-08-01 | 山东大学 | Disulfide bond-containing N-acetyl-L-cysteine derivative and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA720096A (en) * | 1965-10-19 | Joullie Maurice | S-carboxymethyl cysteine composition | |
| US3326762A (en) * | 1963-12-02 | 1967-06-20 | Rech S Pharma Et Scient | Nail strengthener containing s-carboxy-methyl-cysteine and salts thereof |
| EP0546272A1 (en) * | 1991-12-12 | 1993-06-16 | DOMPE' FARMACEUTICI S.p.A. | S-carboxymethylcysteine lysine salt monohydrate and a process for the preparation thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6270312A (en) * | 1985-09-20 | 1987-03-31 | Lion Corp | Composition for oral cavity application |
-
2012
- 2012-07-06 CN CN201210234440.4A patent/CN102863364B/en active Active
- 2012-07-06 CN CN201210234482.8A patent/CN102863365B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA720096A (en) * | 1965-10-19 | Joullie Maurice | S-carboxymethyl cysteine composition | |
| US3326762A (en) * | 1963-12-02 | 1967-06-20 | Rech S Pharma Et Scient | Nail strengthener containing s-carboxy-methyl-cysteine and salts thereof |
| EP0546272A1 (en) * | 1991-12-12 | 1993-06-16 | DOMPE' FARMACEUTICI S.p.A. | S-carboxymethylcysteine lysine salt monohydrate and a process for the preparation thereof |
Non-Patent Citations (2)
| Title |
|---|
| 郑岚等: "药用氨基酸复合盐的合成研究", 《化学试剂》 * |
| 陈敏元: "L-半胱氨酸盐酸盐水合物及其应用和合成概况", 《浙江化工》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014005543A1 (en) * | 2012-07-06 | 2014-01-09 | 广州白云山制药股份有限公司广州白云山制药总厂 | S-(carboxymethyl)-cysteine pharmaceutical compound and preparation method and use thereof |
| US10251854B2 (en) | 2012-07-06 | 2019-04-09 | Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. | S-(carboxymethyl)-cysteine pharmaceutical compound and preparation method and use thereof |
| CN105311009A (en) * | 2014-07-31 | 2016-02-10 | 广州白云山医药集团股份有限公司白云山制药总厂 | Application of S-(carboxymethyl)-L-cysteine to preparation of medicines for preventing and treating respiratory system diseases |
| TWI745289B (en) * | 2015-04-22 | 2021-11-11 | 大陸商江蘇恆瑞醫藥股份有限公司 | A crystalline form of cyclin-dependent protein kinase inhibitor and preparation methods thereof |
| TWI665202B (en) * | 2016-08-01 | 2019-07-11 | 香港商永展國際有限公司 | Crystal of 5-((2-(6-amino)-9h-purin-9-yl)ethyl)amino)pentan-1-ol |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102863365B (en) | 2014-04-16 |
| CN102863364B (en) | 2014-06-25 |
| CN102863364A (en) | 2013-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102863365B (en) | Crystalline pharmaceutical compound and preparation method and usage thereof | |
| KR20160040452A (en) | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | |
| JP6656316B2 (en) | How to use cucumbers, how to use cucumbers extract and how to use drug mixtures | |
| BR112015022008A2 (en) | substituted aromatic compounds and related methods for the treatment of fibrosis | |
| CN101585859B (en) | Novel scutellarin derivative as well as preparation method and pharmaceutical composition thereof | |
| JP2022503890A (en) | A salt formed by 2- (1-acyloxy-N-pentyl) benzoic acid and a basic amino acid or aminoguanidine, and a method and use thereof. | |
| WO2021179711A1 (en) | Process for extracting compounds from dendrobium nobile and use thereof | |
| WO2011035734A1 (en) | Relinqing extract, preparative method and use thereof | |
| CN109789117A (en) | The method for treating acute kidney injury | |
| JP7050336B2 (en) | Deuterated compounds and their pharmaceutical uses | |
| CN103284991B (en) | Food compositions | |
| CN108017656A (en) | Camptothecin derivative and its application in antitumor drug is prepared | |
| BRPI0708554A2 (en) | use of an extract of the plant species siphonochilus aethiopicus, composition, and use of a compound | |
| CN102389434B (en) | Medicinal composition for treating ischemic cerebrovascular disease, and preparation method thereof | |
| CN104610153B (en) | Ozagrel meglumine salt, as well as composition, preparation method and application thereof | |
| CN104829467A (en) | Ambroxol hydrochloride dihydrate compound | |
| CN109303785B (en) | Application of lobetyolin analog compound in preparation of medicine for treating arrhythmia | |
| CN107056877B (en) | A kind of steroid compound and application thereof | |
| CN102775405B (en) | High-solubility doxofylline compound | |
| CN105237487B (en) | The chalcone of base containing ligustrazine virtue oxygen alkane acid compounds, preparation method and applications | |
| CN102973657A (en) | Scutellaria baicalensis, manchurian lilac bark and dahurian rhododendron leaf cough-arresting mixture and preparation method thereof | |
| CN110123797B (en) | New application of dihydrochalcone compound Renifolin F | |
| JP2021515049A (en) | Posaconazole phosphate monocholine salt, its preparation method and use | |
| US10251854B2 (en) | S-(carboxymethyl)-cysteine pharmaceutical compound and preparation method and use thereof | |
| CN102731430B (en) | Novel febuxostat crystal form, its preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Baiyun District of Guangzhou City, Guangdong province 510515 street and with the Cloud Road No. 88 Patentee after: GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD., BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY Patentee after: Guangzhou Institute of Respiratory Disease Address before: Baiyun District of Guangzhou City, Guangdong province 510515 street and with the Cloud Road No. 88 Patentee before: Baiyunshan Pharmaceutical General Factory, Baiyunshan Pharmaceutical Co., Ltd, G Patentee before: Guangzhou Institute of Respiratory Disease |